Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-?).

Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.

Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Abstract: The invention provides methods for treating age-related macular degeneration by administering (i) peptide compositions, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and said peptide compositions. Also provided are methods for diagnosing age-related macular degeneration and monitoring its progression.

Abstract: The invention provides methods for treating age-related macular degeneration by administering (i) peptide compositions, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and said peptide compositions. Also provided are methods for diagnosing age-related macular degeneration and monitoring its progression.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.

Abstract: The present invention is directed to methods of treating and diagnosing age-related macular degeneration.

Abstract: The present invention is directed to methods of diagnosing the presence, severity, or predisposition for development of age-related macular degeneration in a patient based on the frequency of IL-17RC+ cells and or methylation of the promoter of IL17RC gene. Methods of treated age-related macular degeneration are also described.

Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.